Heron Therapeutics
HRTX
174 hedge funds and large institutions have $321M invested in Heron Therapeutics in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 57 increasing their positions, 55 reducing their positions, and 26 closing their positions.
413% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $232K
6.2% more ownership
Funds ownership: 106.28% → 112.48% (+6.2%)
4% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 55
6% less funds holding
Funds holding: 186 → 174 (-12)
35% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 26
48% less capital invested
Capital invested by funds: $621M → $321M (-$299M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$40.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$13.7M |
| 3 |
Walleye Capital
New York
|
+$3.39M |
| 4 |
JP Morgan Chase
New York
|
+$3.05M |
| 5 |
BlackRock
New York
|
+$2.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$20.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.92M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.24M |
| 4 |
Goldman Sachs
New York
|
-$4.04M |
| 5 |
Millennium Management
New York
|
-$3.9M |
HRTX Hedge Fund Activity: Q2 2022 in Review
174 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2022, worth a combined $321M — down 48% from $621M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of HRTX and 17 opened new positions — a net loss of 9 holders — while 55 trimmed existing stakes and 57 added.
The largest buyer was UBS O'Connor, opening a new position worth an estimated $40.7M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $20.1M sold.
- 174 institutional investors held Heron Therapeutics (HRTX) as of Q2 2022, down from 186 in Q1 2022.
- Funds reported $321M of Heron Therapeutics stock for Q2 2022, down 48% quarter-over-quarter.
- 17 funds opened new Heron Therapeutics positions in Q2 2022 and 26 closed out, a net change of -9 holders.
- The largest Heron Therapeutics buyer in Q2 2022 was UBS O'Connor, an estimated $40.7M added.
- The largest Heron Therapeutics seller in Q2 2022 was PFM Health Sciences, an estimated $20.1M sold.
Based on aggregated 13F filings for Q2 2022.